Clinical trials: Solid Tumor Cancer Treatment With Immunotherapy
Neuroblastoma, Sarcoma
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Background: Pediatric solid tumors (Ewing's sarcoma, rhabdomyosarcoma, and neuroblastoma) are often difficult to cure with standard treatment.
- Conditions
- Neuroblastoma, Sarcoma, Rhabdomyosarcoma-Embryonal, Rhabdomyosarcoma- Alveolar
- Trial name
- NCT00923351
- Testing
- Tumor Purged/CD25 Depleted Lymphocytes, Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine, rhIL-7
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms, Neoplasm Malignant
AIMS Cancer Outcomes Study
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in…
- Conditions
- Neoplasms, Neoplasm Malignant, Advanced Cancer, Advanced Solid Tumor
- Trial name
- ACOS (NCT04495790)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Advanced Integrative Medical Science Institute
Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
This is a two-part, biomarker-guided Phase 1/2 study evaluating the safety, feasibility, and preliminary anti-tumor activity of off-the-shelf dual-target CAR-NK cells in participants with advanced or metastatic NSCLC whose tumors…
- Trial name
- DUO-NK-NSCLC (NCT07467863)
- Testing
- Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive Care
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Biotech
Disseminated Neuroblastoma, Recurrent Neuroblastoma
Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
Previous research has demonstrated that investigators can coat (arm) T cells with a special molecule called GD2 bispecific antibody that will help T cells recognize neuroblastoma and osteosarcoma cells and kill them.
- Trial name
- NCT02173093
- Testing
- IL-2, GD2Bi-aATC, GM-CSF
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia
Advanced Solid Tumor
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or…
- Trial name
- NCT07070232
- Testing
- BNT326, Pumitamig, Itraconazole
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 1,438 people
- Sponsor
- BioNTech SE
Unspecified Adult Solid Tumor, Protocol Specific
Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer
RATIONALE: Vaccines made from a person's white blood cells mixed with peptides may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00057915
- Testing
- CEA peptide 1-6D
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Duke University
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid…
- Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer
- Trial name
- NCT05945823
- Testing
- Futibatinib, Pembrolizumab, Cisplatin
- Where
- 22 sites in United States, France and 2 more
- Volunteers
- 53 people
- Sponsor
- Taiho Oncology, Inc.
Stage IV Melanoma, Recurrent Melanoma
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more…
- Trial name
- NCT00003552
- Testing
- allogeneic lymphocytes, anti-thymocyte globulin, cyclophosphamide
- Where
- United States
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Stage IV Melanoma, Stage III Melanoma
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will…
- Conditions
- Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma
- Trial name
- NCT00003647
- Testing
- allovectin-7, allovectin-7/dacarbazine, dacarbazine
- Where
- 44 sites in United States
- Sponsor
- Vical
B2 Thymoma, Thymic Carcinoma
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma.
- Trial name
- SELECT-NK-THYM (NCT07598955)
- Testing
- Cyclophosphamide, Fludarabine, EB-CAR30-NK
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Squamous Cell Carcinoma of Head and Neck
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
The primary objective of this study was to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who had previously received anti-PD-(L)1 therapy but who had not achieved a CR.
- Trial name
- NCT04144517
- Testing
- Nemvaleukin Alfa, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Mural Oncology, Inc
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Observational Study of Sex Differences in Symptoms During Immune Checkpoint Inhibitor Treatment for People With Cancer
This study aims to learn more about symptoms that patients experience while receiving immunotherapy for cancer.
- Trial name
- NCT06562777
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- OHSU Knight Cancer Institute
Advanced Cancer, Angiosarcoma
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1…
- Conditions
- Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
- Trial name
- NCT03860272
- Testing
- Botensilimab, Balstilimab
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 499 people
- Sponsor
- Agenus Inc.
Cancer, Solid Tumor
A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin
The purpose of this study is to test the safety and tolerability of 2141-V11 in people who have cancer that does not respond to standard treatment and who have skin lesions (skin tumors) associated with their cancer.
- Conditions
- Cancer, Solid Tumor, Cancer of Skin
- Trial name
- NCT04059588
- Testing
- 2141 V-11
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Rockefeller University
Solid Tumor, Advanced Cancer
A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid Tumors
This is an open-label, dose escalation study of the safety and tolerability of oncolytic virus injection(RT-01) when administered via intratumoral injection in patients with advanced solid tumors.
- Trial name
- NCT05136937
- Testing
- Oncolytic Virus Injection(RT-01)
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Wuxi People's Hospital
Clear Cell RCC
A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma
This is an open label, single-centre phase 1/2 study involving a single dose of Temferon, an investigational Advanced Therapy Medicinal Product (ATMP), to treat patients with metastatic clear cell renal cell carcinoma (RCC) with…
- Trial name
- TEM-GU (NCT06716853)
- Testing
- Temferon, Pembrolizumab, Cabozantinib
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Genenta Science
Malignant Solid Neoplasms
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
The MOST Plus study is a two-period phase II clinical trial, conducted in patients with all types of progressive solid tumors after at least 1 prior systemic treatment regimen for advanced disease (in the absence of a validated…
- Trial name
- MOST plus (NCT02029001)
- Testing
- Nilotinib (400 mg BID), Everolimus (10 mg QD), Sorafenib (400 mg BID)
- Where
- 7 sites in France
- Volunteers
- 900 people
- Sponsor
- Centre Leon Berard
Advanced Solid Tumors
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Immune therapies work with the body's immune system to treat a number of cancers. They work with T-cells, a type of white blood cell, to target and attack specific tumors.
- Trial name
- NCT05083481
- Testing
- ASP1570, pembrolizumab, Trifluridine + Tipiracil
- Where
- 30 sites in United States, China and 4 more
- Volunteers
- 226 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Liver Metastases, Non-Small Cell Lung Cancer
Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
This study aims to evaluate the effectiveness and safety of combining low-dose radiotherapy to the intestines with immune checkpoint inhibitors (ICIs) in patients with liver metastases from solid tumors.
- Conditions
- Liver Metastases, Non-Small Cell Lung Cancer, Colorectal Cancer (Diagnosis), Pancreatic Cancer Metastatic
- Trial name
- ILDR-ICI-LM (NCT07875465)
- Testing
- Intestinal Low-Dose Radiotherapy (ILDR), PD-1/PD-L1 inhibitors, Combined Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Bing Xia
Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
This phase II trial studies the side effects and best dose of radiation therapy and to see how well it works in treating patients with cancer that has spread to other places in the body (metastatic) or has increased in size after…
- Trial name
- NCT02710253
- Testing
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy
- Where
- 5 sites in United States
- Volunteers
- 214 people
- Sponsor
- M.D. Anderson Cancer Center